Canaccord lowered the firm’s price target on Clover Health (CLOV) to $4.10 from $4.50 and keeps a Buy rating on the shares. The firm said they reported solid Q2 results however the insurance benefit expense ration came in higher than expected which created some concern.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV: